ObjectivesWhile numerous medical facilities have been forced to suspend oncological surgery due to system overload, debate has emerged on using non-surgical options on cancer cases during the pandemic. The goal of our study was to analyze, in a retrospective cohort study, the results of gynecological cancer surgery and evaluate postoperative complications in a single center in one of the most affected areas in Europe.MethodsWe retrospectively analyzed the records of patients who were referred between March 2020 and May 2020 for primary surgical treatment of breast, endometrial, ovarian, cervical, or vulvar cancer.ResultsThe study included a total of 126 patients. Median age was 60 years (range 29–89). Patients were referred with breast (76/126, 60.3%), endometrial (29/126, 23%), ovarian (14/126, 11.1%), cervical (5/126, 4%), or vulvar cancer (2/126, 1.6%). Polymerase chain reaction (PCR) test for detection of severe acute respiratory syndrome coronavirus 2 (SARS-COV-2) was only conducted in 50% of cases due to the low availability of tests during the first phase of our study, and was indicated only in suspected cases according to the healthcare authorities' protocol. Median hospital stay was 1 day (range 0–18). Excluding breast surgery, laparoscopy was the most used procedure (43/126, 34.1%). 15 patients had a postoperative complication (15/126, 11.9%); only in 2 patients (2/15 13.3%) were there reports of Clavien–Dindo grade 3 or 4 complications. 6 patients tested positive for COVID-19 following a PCR diagnostic test, and these surgeries were cancelled.ConclusionsAdequate protective measures in the setting of COVID-19 free institutions enabled the continuity of cancer surgery without significant compromise of the safety of patients or healthcare workers.

Introduction/Background* The vast majority of patients with cancers of uterus, the uterine cervix, and a significant number of patients with cancer of the ovary survive their disease and are considered to be cured. However, the diagnosis of cancer and its treatment can affect quality of life (QoL) adversely. There is no study reporting Qol from Oman and there are only a few studies from Arabic-speaking countries. We report the QoL of Omani women living with gynecological cancers. Methodology We interviewed 20 Omani women attending the medical oncology clinic in a cancer center in Oman using the validated Arabic version of EORTC QLQ-C30 scale. Result(s)* The majority of women were married (60%) with a median age of 40 years, 65% had ovarian or endometrial cancers, 45% had at least a baccalaureate and 40% were working. The majority (78.9%) received both chemotherapy and surgery for their treatment. Almost 45% women had trouble with long walks, needed to take rest, experienced shortness of breath and disturbed sleep, felt tired, had difficulty in concentrating, and felt irritable. However, 80% rated their overall health as 6 and 7 on a scale ranging from 1 to 7, with 7 being excellent. Furthermore, 95% rated their quality of life in the past week as 5, 6 and 7, with 7 being excellent. Conclusion*The results indicate that despite the physical and social struggle, Omani women who survive gynecological cancers regard their health-related QoL as very good to excellent.

No abstract

e11517 Background: Aim:To study the relation of positive(pos) SN and mMTS or ITC in negative(neg) SN at surgery with tumor pathological(pathol) features (grade;carcinoma type;Ki67;Her2;hormonal status;tumor size). Methods: Cohort of 271 patients with clinically and ultrasonographically node-neg pT1-2 breast cancer and high grade or extended intraductal who received breast cancer surgery with SN biopsy alone in the last 2 years was studied. No previous chemotherapy was administered. Hormone(ER/RP) and Ki67 status were analyzed by inmunohistochemistry(IHC) while HER2 by FISH. Presence of mMTS and ITC were studied by IHC(AE1-AE3). Statistical analysis was conducted to ascertain significant relation among pos-SN or detection of mMTS/ITC in neg-SN and each of the tumor pathol features (test U-Mann-Whitney). Results: Data from 263 patients were analyzed (28 pos-SN;235 neg-SN;8 technique failures). Carcinoma type: Ductal (158;60%);lobular (46;17.5%);in-situ(53;20.2%);others(6;2.3%). Infiltrative cancer:(56% grade 2;20% grade 3;10% Her2+;9% triple-neg;81% pos-RE/RP). In-situ:(28% grade 2;64% grade 3;39% Her2+;55% pos-RE/RP). Mean pathological size 16.2mm(1-118) for infiltrative tumor and 20.1mm(1-90) for in-situ. Mean of SN found at surgery 1.98(1-5). In neg-SN, 35 cases with mMTS(14;6.2%) or ITC(21;9.2%) were found. No statistically significant relation was established between the finding of mMTS or ITC and any of the pathol features at in-situ or infiltrative tumors. In pos-SN a statistically significant relation between pos-SN and pathol size was found (p=0.003; mean pathol size 20.16mm and 15.69mm for pos and neg-SN). Conclusions: A significant relation was established with pathol size and pos-SN. In patients with neg-SN no significant relationship was found between detection of mMTS or ITC and the pathol features of the tumor.

levels were positive in their second-look. 70% of patients with residual tumors having the greatest diameter less than or equal to 2 cm had normal CA125 with a mean value of 21 u/ml. 42% of patients with tumors having the greatest diameter greater than 2 cm had normal CA125, while all the 8 patients with no macroscopic tumor during surgery had normal CA125 level. These results show that the residual tumor size found in the second-look was related to the serum CA125 level. Conclusion As CA125 levels within normal limits gave more false negatives, the necessity of second-look surgery can not be judged by serum CA125 assay though elevated CA125 levels do predict the presence of tumor.